{"filing":{"accession_number":"0001437749-26-031280","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"mbrx20260925_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031280/mbrx20260925_8k.htm"},"events":[{"id":35283,"run_id":32494,"accession_number":"0001437749-26-031280","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This disclosure announces the publication of a peer-reviewed cardiac safety analysis of Annamycin in a medical journal, demonstrating favorable safety findings across five clinical trials. While the filing is made under Item 7.01 (Regulation FD Disclosure) rather than a dedicated 8-K item, the announcement of positive clinical trial results for a lead drug candidate represents a material operational/clinical milestone that would affect investor assessment of the company's development progress and product viability. This is not a traditional earnings release, but rather a clinical validation event for an early-stage biotech company's pipeline asset.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39284,"accession_number":"0001437749-26-031280","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces the publication of a peer-reviewed cardiac safety analysis of Annamycin in a medical journal, demonstrating favorable safety findings across five clinical trials. While the filing is made under Item 7.01 (Regulation FD Disclosure) rather than a dedicated 8-K item, the announcement of positive clinical trial results for a lead drug candidate represents a material operational/clinical milestone that would affect investor assessment of the company's development progress and product viability. This is not a traditional earnings release, but rather a clinical validation event for an early-stage biotech company's pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:10:10.606888+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39284,"accession_number":"0001437749-26-031280","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces the publication of a peer-reviewed cardiac safety analysis of Annamycin in a medical journal, demonstrating favorable safety findings across five clinical trials. While the filing is made under Item 7.01 (Regulation FD Disclosure) rather than a dedicated 8-K item, the announcement of positive clinical trial results for a lead drug candidate represents a material operational/clinical milestone that would affect investor assessment of the company's development progress and product viability. This is not a traditional earnings release, but rather a clinical validation event for an early-stage biotech company's pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:10:10.606888+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-28"}]}